Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

– MB-106: CR rate of 38% (N=8) with durability up to 8 months – Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) – MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated subjects (N=15) – MB-107 Phase 1B/2 median progression free survival (PFS) of 3.4 months for subjects dosed at or below 330 mg/m2 and less than 3 prior therapies (N=9) – 100% of Annamycin subjects in multiple studies (N=66) continue to show no signs of cardiotoxicity during study HOUSTON, Nov. 13, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today provided a preliminary update on recent clinical activity and expected near term milestones across its clinical development pipeline in its quarterly filing with the Securities and Exchange Commission.

The release as fetched from its publisher. moleculin.com ↗